Apogee Therapeutics
APGE
224 hedge funds and large institutions have $6.64B invested in Apogee Therapeutics in 2026 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 103 increasing their positions, 53 reducing their positions, and 30 closing their positions.
114% more call options, than puts
Call options by funds: $78.5M | Put options by funds: $36.7M
94% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 53
67% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 30
26% more capital invested
Capital invested by funds: $5.27B → $6.64B (+$1.37B)
11.67% more ownership
Funds ownership: 102.11% → 113.78% (+12%)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
9% more funds holding
Funds holding: 206 → 224 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$550M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$75.3M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$42.4M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$39.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$34.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$127M |
| 2 |
PA
Perceptive Advisors
New York
|
-$57.4M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$40.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$37.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.9M |
APGE Hedge Fund Activity: Q1 2026 in Review
224 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q1 2026, worth a combined $6.64B — up 26% from $5.27B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new APGE positions and 30 closed out — a net gain of 20 holders — while 103 added to existing stakes and 53 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $550M. The largest seller was Fairmount Funds Management, cutting an estimated $127M.
- 224 institutional investors held Apogee Therapeutics (APGE) as of Q1 2026, up from 206 in Q4 2025.
- Funds reported $6.64B of Apogee Therapeutics stock for Q1 2026, up 26% quarter-over-quarter.
- 50 funds opened new Apogee Therapeutics positions in Q1 2026 and 30 closed out, a net change of +20 holders.
- The largest Apogee Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $550M added.
- The largest Apogee Therapeutics seller in Q1 2026 was Fairmount Funds Management, an estimated $127M sold.
Based on aggregated 13F filings for Q1 2026.